Florent Malard News Today : Breaking News, Live Updates & Top Stories | Vimarsana

LYON, France, November 02, 2023--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, announced today that extended results from its Early Access Program of MaaT013 in 111 patients (additional 30 patients included in the Program compared to last year) with aGvHD and the design of its Phase 2b study evaluating MaaT033

Poster 1 presents Early Access Program (EAP) data for 111 patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013.Poster 2 details the Phase 2b randomized, double-blinded study evaluating MaaT033 to enhance overall survival in allogenic hematopoietic cell transplantation patients.For the seventh conse...

Data, which were previously presented at the American Society of Hematology (ASH) Annual Meeting in December 2022, includes results of 81 patients with gastrointestinal acute Graft-versus-Host Disease

Data, which were previously presented at the American Society of Hematology (ASH) Annual Meeting in December 2022, includes results of 81 patients with gastrointestinal acute Graft-versus-Host Disease (GI-aGvHD) treated with MaaT013 as part of a compassionate use program in France, and results of the Phase 1b CIMON...

MaaT Pharma will host a webcast conference for the investment community in conjunction with the American Society of Haematology Annual Meeting on December 12, 2022 Hervé Affagard, CEO and